Protalix BioTherapeutics Inc (FRA:PBDA) Stock Price, Trades & News

Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.

Financial Strength

8/10

Name	Current	Vs Industry
Cash-To-Debt	4.42
Equity-to-Asset	0.65
Debt-to-Equity	0.13
Debt-to-EBITDA	0.35
Interest Coverage	18.63
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	0.37	Distress Grey Safe
Beneish M-Score	-1.57	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

1/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	-11.9
	3-Year EBITDA Growth Rate	44.5
	3-Year EPS without NRI Growth Rate	36.3
	3-Year FCF Growth Rate	31

Momentum Rank

2/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	44.74
	9-Day RSI	46.02
	14-Day RSI	47.83
	3-1 Month Momentum %	27.15
	6-1 Month Momentum %	-17.2
	12-1 Month Momentum %	58.02

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.94
	Quick Ratio	1.91
	Cash Ratio	1.3
	Days Inventory	384.76
	Days Sales Outstanding	47.22
	Days Payable	82.65

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-14.3
	Shareholder Yield %	-1.68

Profitability Rank

2/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	69.2
	Operating Margin %	28.89
	Net Margin %	23.5
	EBITDA Margin %	32.6
	FCF Margin %	9.56
	OCF Margin %	12.35
	ROE %	32.7
	ROA %	20.78
	ROIC %	59.09
	3-Year ROIIC %	284.51
	ROC (Joel Greenblatt) %	95.11
	ROCE %	38.09
	Years of Profitability over Past 10-Year	2
	Moat Score	4
	Tariff Resilience Score	7

GF Value Rank

7/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	10.17
	Forward PE Ratio	11.2
	PE Ratio without NRI	10.17
	Price-to-Owner-Earnings	35.78
	PS Ratio	2.38
	PB Ratio	2.64
	Price-to-Tangible-Book	2.63
	Price-to-Free-Cash-Flow	25.7
	Price-to-Operating-Cash-Flow	19.65
	EV-to-EBIT	6.56
	EV-to-EBITDA	6.17
	EV-to-Revenue	2.02
	EV-to-Forward-Revenue	1.92
	EV-to-FCF	19.96
	Price-to-GF-Value	1.06
	Price-to-Median-PS-Value	1.18
	Price-to-Graham-Number	1.09
	Price-to-Net-Current-Asset-Value	3.57
	Price-to-Net-Cash	100
	Earnings Yield (Greenblatt) %	15.23
	FCF Yield %	3.97

Financials (Next Earnings Date:2026-11-13 Est.)

Annual Quarterly TTM

FRA:PBDA's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Protalix BioTherapeutics Inc Executives

Details

GF Value™: €1.88

FRA:PBDA

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 4 Severe warning signs with PBDA. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	69.463
	EPS (TTM) (€)	0.199
	Beta	-0.5637
	3-Year Sharpe Ratio	0.49
	3-Year Sortino Ratio	0.81
	Volatility %	68.21
	14-Day RSI	47.83
	14-Day ATR (€)	0.08474
	20-Day SMA (€)	2.04985
	12-1 Month Momentum %	58.02
	52-Week Range (€)	1.25 - 2.66
	Shares Outstanding (Mil)	80.57

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	6
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Protalix BioTherapeutics Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Protalix BioTherapeutics Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-11-13 08:00	In 87 days
Third quarter earnings results for 2026	2026-11-13	In 86 days
Second quarter earnings conference call for 2026	2026-08-12 08:00	2.10 (-0.48%)
Second quarter earnings results for 2026	2026-08-12	2.10 (-0.48%)
General meeting for 2026	2026-06-25 08:00	1.95 (+4.39%)
First quarter earnings conference call for 2026	2026-05-13 08:00	1.63 (+1.11%)
First quarter earnings results for 2026	2026-05-13	1.63 (+1.11%)
Fourth quarter earnings conference call for 2025	2026-03-18 08:00	2.38 (-2.46%)
Annual report for 2025	2026-03-18	2.38 (-2.46%)
Fourth quarter earnings results for 2025	2026-03-18	2.38 (-2.46%)

Show

Entries

Protalix BioTherapeutics Inc Frequently Asked Questions

What is Protalix BioTherapeutics Inc(FRA:PBDA)'s stock price today?

The current price of FRA:PBDA is €2.00. The 52 week high of FRA:PBDA is €2.66 and 52 week low is €1.25.

When is next earnings date of Protalix BioTherapeutics Inc(FRA:PBDA)?

The next earnings date of Protalix BioTherapeutics Inc(FRA:PBDA) is 2026-11-13 Est..

Does Protalix BioTherapeutics Inc(FRA:PBDA) pay dividends? If so, how much?

Protalix BioTherapeutics Inc(FRA:PBDA) does not pay dividend.

Press Release

	Subject	Date
	Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026	2026-08-05
	Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results	2026-05-13
	Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results	2026-03-18
	Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026	2026-03-11
	Protalix BioTherapeutics Letter to Stockholders	2026-01-05
	Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement	2025-12-17
	Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results	2025-11-13
	Protalix BioTherapeutics to Present at Investor Summit Virtual	2025-09-11
	Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference	2025-09-02
	Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results	2025-08-14

10/Page

Articles on Protalix BioTherapeutics Inc

FRA:PBDA

Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026

Aug 05, 2026

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.